RU2017113351A - Ингибиторы ezh2 человека и способы их применения - Google Patents

Ингибиторы ezh2 человека и способы их применения Download PDF

Info

Publication number
RU2017113351A
RU2017113351A RU2017113351A RU2017113351A RU2017113351A RU 2017113351 A RU2017113351 A RU 2017113351A RU 2017113351 A RU2017113351 A RU 2017113351A RU 2017113351 A RU2017113351 A RU 2017113351A RU 2017113351 A RU2017113351 A RU 2017113351A
Authority
RU
Russia
Prior art keywords
level
dimethylation
control
trimethylation
ratio
Prior art date
Application number
RU2017113351A
Other languages
English (en)
Other versions
RU2765155C2 (ru
RU2017113351A3 (ru
Inventor
Роберт Аллен КОУПЛЕНД
Виктория Мари РИЧОН
Маргарет Дэвис СКОТТ
Кристофер Джон СНИРИНГЕР
Кевин Уэйн КУНТЦ
Сара Кейтлин НАТСОН
Рой Макфарлэйн ПОЛЛОК
Original Assignee
Эпизайм, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45811204&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2017113351(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эпизайм, Инк. filed Critical Эпизайм, Инк.
Publication of RU2017113351A publication Critical patent/RU2017113351A/ru
Publication of RU2017113351A3 publication Critical patent/RU2017113351A3/ru
Application granted granted Critical
Publication of RU2765155C2 publication Critical patent/RU2765155C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/12—Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Claims (15)

1. Способ, включающий:
a) получение образца ткани от индивидуума;
b) выявление уровня диметилирования (me2) H3-K27, если оно присутствует в указанном образце ткани, и сравнение указанного уровня диметилирования (me2) с контрольным уровнем диметилирования (me2);
c) необязательно выявление уровня триметилирования (me3) H3-K27, если оно присутствует в указанном образце ткани, и сравнение указанного уровня триметилирования (me3) с контрольным уровнем триметилирования (me3),
где указанный индивидуум является отвечающим на ингибитор EZH2, когда указанный уровень диметилирования (me2) отсутствует или ниже указанного контрольного уровня диметилирования (me2), или когда указанный уровень триметилирования (me3) является таким же или более высоким, чем указанный контрольный уровень триметилирования (me3), и указанный уровень диметилирования (me2) отсутствует или ниже указанного контрольного уровня диметилирования (me2).
2. Способ по п.1, дополнительно включающий:
d) получение соотношения уровня диметилирования (me2) и уровня триметилирования (me3) H3-K27 в указанном образце ткани, для получения тестируемого соотношения, и сравнение тестируемого соотношения с контрольным соотношением;
где указанный индивидуум является отвечающим на ингибитор EZH2, когда указанное тестируемое соотношение является более низким, чем указанное контрольное соотношение.
3. Способ по п.1, где указанный индивидуум имеет рак.
4. Способ по п.1, где указанное выявление проводят с помощью анализа, выбранного из анализа с использованием вестерн-блоттинга, иммуногистохимии (IHC), иммунофлуоресценции (IF) и масс-спектрометрии (МС).
5. Способ по п.1, где указанное выявление включает приведение в контакт указанного образца ткани со средством, которое специфично связывается с диметилированным H3-K27 и/или триметилированным H3-K27.
6. Способ по п.5, где указанное средство представляет собой антитело, полипептид, аптамер или их фрагмент.
7. Способ по п.3, где указанный рак выбран из фолликулярной лимфомы и диффузной крупно-B-клеточной лимфомы (DLBCL).
8. Способ по любому из пп.1-7, где у указанного индивидуума экспрессируется мутантный по Y641 полипептид EZH2.
9. Способ по п.8, где указанный мутант по Y641 выбран из Y641F, Y641H, Y641N и Y641S.
RU2017113351A 2010-09-10 2011-09-12 Ингибиторы ezh2 человека и способы их применения RU2765155C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38168410P 2010-09-10 2010-09-10
US61/381,684 2010-09-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2013115928A Division RU2618475C2 (ru) 2010-09-10 2011-09-12 Ингибиторы ezh2 человека и способы их применения

Publications (3)

Publication Number Publication Date
RU2017113351A true RU2017113351A (ru) 2019-01-25
RU2017113351A3 RU2017113351A3 (ru) 2020-08-26
RU2765155C2 RU2765155C2 (ru) 2022-01-26

Family

ID=45811204

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2013115928A RU2618475C2 (ru) 2010-09-10 2011-09-12 Ингибиторы ezh2 человека и способы их применения
RU2017113351A RU2765155C2 (ru) 2010-09-10 2011-09-12 Ингибиторы ezh2 человека и способы их применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2013115928A RU2618475C2 (ru) 2010-09-10 2011-09-12 Ингибиторы ezh2 человека и способы их применения

Country Status (14)

Country Link
US (6) US8895245B2 (ru)
EP (1) EP2614369B1 (ru)
JP (5) JP6389036B2 (ru)
KR (3) KR102061353B1 (ru)
CN (2) CN103261890B (ru)
AU (4) AU2011298987B2 (ru)
BR (1) BR112013005806B1 (ru)
CA (2) CA3176977A1 (ru)
DK (1) DK2614369T3 (ru)
ES (1) ES2570380T3 (ru)
HU (1) HUE028977T2 (ru)
PL (1) PL2614369T3 (ru)
RU (2) RU2618475C2 (ru)
WO (1) WO2012034132A2 (ru)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) * 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
ES2570380T3 (es) 2010-09-10 2016-05-18 Epizyme Inc Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
AU2012315566A1 (en) 2011-09-30 2014-04-17 Glaxosmithkline Llc Methods of treating cancer
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc METHYLATION MODIFICATION ENZYME MODULATORS, COMPOSITIONS AND USES THEREOF
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013120104A2 (en) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
RU2637441C2 (ru) 2012-02-27 2017-12-04 Бритиш Коламбиа Кансер Эдженси Бранч Репрограммирование эффекторных белковых взаимодействий для исправления эпигенетических дефектов в злокачественной опухоли
AU2013232229B2 (en) * 2012-03-12 2017-11-23 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
RS55690B1 (sr) 2012-04-13 2017-07-31 Epizyme Inc So inhibitora ljudske histonske metiltransferaze ezh2
NZ700759A (en) 2012-04-13 2017-03-31 Epizyme Inc Combination therapy for treating cancer
KR20150030205A (ko) 2012-05-16 2015-03-19 라나 테라퓨틱스, 인크. Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
WO2013173608A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating mecp2 expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
JP2015523853A (ja) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Ａｔｐ２ａ２発現を調節するための組成物及び方法
WO2013173645A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating utrn expression
JP2015518710A (ja) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法
AU2013331380B2 (en) * 2012-10-15 2018-03-22 Epizyme, Inc. Substituted benzene compounds
MX2015004771A (es) * 2012-10-15 2016-01-08 Epizyme Inc Metodos para tratar cancer.
JP6584952B2 (ja) 2012-11-01 2019-10-02 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３キナーゼアイソフォームモジュレーターを用いる癌の治療
US10130637B2 (en) 2012-11-02 2018-11-20 Duke University Inhibition of histone methyltransferase for cardiac reprogramming
EP2908843B1 (en) 2012-11-19 2019-09-04 Agency For Science, Technology And Research Treating cancer
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US9701666B2 (en) 2012-12-21 2017-07-11 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9346761B2 (en) 2013-03-14 2016-05-24 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970134B1 (en) 2013-03-14 2018-02-28 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
EP2968565A2 (en) * 2013-03-14 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
KR102028793B1 (ko) 2013-03-14 2019-10-07 에피자임, 인코포레이티드 아르기닌 메틸기 전이효소 억제제 및 이의 용도
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970131B1 (en) 2013-03-14 2017-11-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2970194A1 (en) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014176047A1 (en) * 2013-04-25 2014-10-30 Novartis Ag Markers for ezh2 inhibitors
RU2705204C2 (ru) 2013-05-30 2019-11-06 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ piз-киназы
US20160122760A1 (en) * 2013-06-07 2016-05-05 Rana Therapeutics, Inc. Compositions and methods for modulating foxp3 expression
US9828393B2 (en) * 2013-07-22 2017-11-28 The Regents Of The University Of Colorado, A Body Corporate Silylalkyloxyaryl compounds and methods for treating cancer
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
MY175778A (en) 2013-10-04 2020-07-08 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MA38949A1 (fr) 2013-10-16 2017-07-31 Eisai R&D Man Co Ltd Forme saline d'hydrochlorure pour inhibition d'ezh2
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201691079A1 (ru) 2013-12-06 2017-03-31 Эпизим, Инк. Комбинированная терапия для лечения онкологического заболевания
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US10603295B2 (en) 2014-04-28 2020-03-31 Massachusetts Eye And Ear Infirmary Sensorineural hair cell differentiation
LT3157527T (lt) * 2014-06-17 2023-07-25 Epizyme, Inc. Ezh2 inhibitoriai, skirti limfomos gydymui
KR101877187B1 (ko) 2014-06-17 2018-07-10 화이자 인코포레이티드 치환된 다이하이드로이소퀴놀린온 화합물
JP6684230B2 (ja) 2014-06-19 2020-04-22 メモリアル スローン ケタリング キャンサー センター Ｅｚｈ２阻害剤への応答についてのバイオマーカー
JP2016044993A (ja) * 2014-08-20 2016-04-04 有限会社マイテック ヒストン化学修飾判定による癌診断方法
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ730365A (en) 2014-10-16 2024-03-22 Epizyme Inc Method for treating cancer
EP3214935A4 (en) 2014-11-06 2018-08-29 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
FI3220916T3 (fi) 2014-11-17 2023-06-19 Epizyme Inc Menetelmä syövän hoitoon n-((4,6-dimetyli-2-okso-1,2-dihydropyridin-3-yyli)metyyli)-5-(etyyli(tetrahydro-2h-pyran-4-yyli)amino)- 4-metyyli-4'-(morfolinometyyli)-[1,1'-bifenyyli]-3-karboksamidilla
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
CR20170285A (es) 2014-12-23 2017-08-21 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
US20180271857A1 (en) 2014-12-23 2018-09-27 University Of Copenhagen Treatment of cancer by inhibiting ezh2 activity
US10758558B2 (en) 2015-02-13 2020-09-01 Translate Bio Ma, Inc. Hybrid oligonucleotides and uses thereof
WO2016164463A1 (en) 2015-04-07 2016-10-13 The General Hospital Corporation Methods for reactivating genes on the inactive x chromosome
SG11201708286PA (en) 2015-04-20 2017-11-29 Epizyme Inc Combination therapy for treating cancer
CN107635965A (zh) * 2015-06-10 2018-01-26 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
WO2017023671A1 (en) * 2015-08-03 2017-02-09 Constellation Pharmaceuticals, Inc. Ezh2 inhibitors and modulation of regulatory t-cell function
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
WO2017053930A2 (en) * 2015-09-25 2017-03-30 Epizyme, Inc. Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor
EP3371601A1 (en) 2015-11-05 2018-09-12 Epizyme Inc Flow cytometry for monitoring histone h3 methylation status
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
GB201700138D0 (en) 2017-01-05 2017-02-22 Senzagen Ab Analytical methods and arrays for use in the same
WO2017184999A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
CN105777718B (zh) * 2016-04-27 2019-03-19 上海应用技术学院 潜在ezh2小分子抑制剂及其合成方法
WO2017210395A1 (en) * 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2019521988A (ja) * 2016-06-17 2019-08-08 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
EP3472161B1 (en) 2016-06-20 2020-03-25 Novartis AG Triazolopyridine compounds and uses thereof
BR112018076443A2 (pt) 2016-06-20 2019-04-09 Novartis Ag formas cristalinas de um composto de triazolopirimidina
MX2018016227A (es) 2016-06-24 2019-07-08 Infinity Pharmaceuticals Inc Terapias de combinacion.
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
EP3548032A2 (en) 2016-12-02 2019-10-09 Epizyme, Inc. Combination therapy for treating cancer
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
AU2018254577A1 (en) 2017-04-21 2019-12-05 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2018231973A1 (en) * 2017-06-13 2018-12-20 Epizyme, Inc. Inhibitors of ezh2 and methods of use thereof
EP3678663A4 (en) 2017-09-05 2021-06-02 Epizyme, Inc. POLYTHERAPY FOR CANCER TREATMENT
EP3697419A4 (en) * 2017-10-17 2021-08-18 Epizyme, Inc. AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF
AU2018354090A1 (en) 2017-10-23 2020-03-12 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
AU2018369841A1 (en) 2017-11-14 2020-05-07 Pfizer Inc. EZH2 inhibitor combination therapies
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
WO2020146263A1 (en) * 2019-01-09 2020-07-16 Epitracker, Inc. Compositions and methods for diagnosis and treatment of neurodegenerative diseases
WO2020219606A1 (en) 2019-04-22 2020-10-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of erk5 inhibitors for treating gliomas in pediatric subjects
EP3959521A1 (en) 2019-04-24 2022-03-02 Institut Curie Biomarkers for predicting resistance to cancer drugs
WO2021035194A1 (en) 2019-08-22 2021-02-25 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
CN110835650B (zh) * 2019-11-21 2022-11-25 徐州医科大学 乳腺癌转移和预后诊断的生物标志物
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价
CN111257405B (zh) * 2020-03-02 2023-08-25 中国人民解放军军事科学院军事医学研究院 一种利用质谱定量技术对基因毒性物质进行鉴定的方法
WO2023025856A1 (en) 2021-08-25 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ezh2 inhibitors for the treatment of aortic valve stenosis
KR20230087155A (ko) 2021-12-09 2023-06-16 동의대학교 산학협력단 황금 추출물을 유효성분으로 포함하는 티로신 키나아제 억제제 내성 항암제 조성물

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
US5716993A (en) 1993-12-27 1998-02-10 Eisai Co., Ltd. Anthranilic acid derivatives
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
BR9914207A (pt) 1998-09-30 2001-07-03 Procter & Gamble Ceto-amidas 2-substituìdas
UA71587C2 (ru) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Translated By PlajАМИДЫ АНТРАНИЛОВОЙ КИСЛОТЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕЧЕБНЫХ СРЕДСТВ
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CN100575345C (zh) 2000-12-28 2009-12-30 盐野义制药株式会社 对2型***素受体具有结合活性的吡啶酮衍生物
US7700293B2 (en) * 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
DE60329981D1 (de) 2002-02-19 2009-12-24 Shionogi & Co Antipruriginosa
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
JP2004217634A (ja) * 2002-12-24 2004-08-05 Takeda Chem Ind Ltd がんの予防・治療剤
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
EP1663194B1 (en) 2003-08-26 2010-03-31 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
CN1286973C (zh) * 2004-04-12 2006-11-29 上海第二医科大学附属瑞金医院 一种组蛋白甲基转移酶及其制备方法
ATE449168T1 (de) 2004-06-01 2009-12-15 Univ North Carolina Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
DE602006019423D1 (de) 2005-06-02 2011-02-17 Univ North Carolina Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
PE20110285A1 (es) 2005-10-19 2011-06-04 Gruenenthal Chemie Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1
ATE510822T1 (de) 2005-10-21 2011-06-15 Merck Sharp & Dohme Kaliumkanalinhibitoren
WO2007053480A2 (en) 2005-10-28 2007-05-10 The University Of North Carolina At Chapel Hill Protein demethylases comprising a jmjc domain
CN101365806B (zh) * 2005-12-01 2016-11-16 医学预后研究所 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
WO2007070818A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2007087015A1 (en) 2006-01-20 2007-08-02 The University Of North Carolina At Chapel Hill Diagnostic and therapeutic targets for leukemia
JP2009537521A (ja) 2006-05-15 2009-10-29 アイアールエム・リミテッド・ライアビリティ・カンパニー テレフタラメート化合物および組成物、ならびにｈｉｖインテグラーゼ阻害剤としてのそれらの使用
US20070287706A1 (en) 2006-05-18 2007-12-13 Dickson John K Jr Certain substituted quinolones, compositions, and uses thereof
WO2008108825A2 (en) 2006-10-10 2008-09-12 Burnham Institute For Medical Research Neuroprotective compositions and methods
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US20090012031A1 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
AU2008319308B2 (en) 2007-10-31 2013-01-31 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
WO2009124137A2 (en) * 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
WO2010017355A2 (en) 2008-08-08 2010-02-11 New York Blood Center Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
WO2010111653A2 (en) 2009-03-27 2010-09-30 The Uab Research Foundation Modulating ires-mediated translation
WO2011011366A2 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
WO2011082044A1 (en) 2009-12-30 2011-07-07 Avon Products, Inc. Topical lightening composition and uses thereof
EP2566479B1 (en) 2010-05-07 2014-12-24 GlaxoSmithKline LLC Azaindazoles
NZ603454A (en) * 2010-05-07 2014-06-27 Glaxosmithkline Llc Indoles useful for treating cellular proliferation diseases such as cancer
ES2534804T3 (es) 2010-05-07 2015-04-28 Glaxosmithkline Llc Indazoles
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) * 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
ES2570380T3 (es) * 2010-09-10 2016-05-18 Epizyme Inc Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5908493B2 (ja) 2010-12-01 2016-04-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ インドール
KR20130124959A (ko) 2010-12-03 2013-11-15 에피자임, 인코포레이티드 히스톤 메틸전달효소의 7-데아자퓨린 조절제 및 그의 사용방법
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
AU2012315566A1 (en) 2011-09-30 2014-04-17 Glaxosmithkline Llc Methods of treating cancer
NZ700759A (en) 2012-04-13 2017-03-31 Epizyme Inc Combination therapy for treating cancer

Also Published As

Publication number Publication date
CN103261890A (zh) 2013-08-21
US20170065628A1 (en) 2017-03-09
RU2765155C2 (ru) 2022-01-26
KR20220035268A (ko) 2022-03-21
RU2618475C2 (ru) 2017-05-03
AU2011298987A1 (en) 2013-03-28
US9333217B2 (en) 2016-05-10
WO2012034132A2 (en) 2012-03-15
EP2614369A2 (en) 2013-07-17
KR20140019770A (ko) 2014-02-17
ES2570380T3 (es) 2016-05-18
JP2021169450A (ja) 2021-10-28
PL2614369T3 (pl) 2016-08-31
US9949999B2 (en) 2018-04-24
CN105797158B (zh) 2019-11-08
KR20200003422A (ko) 2020-01-09
AU2022242157A1 (en) 2022-10-27
US20200397812A1 (en) 2020-12-24
EP2614369B1 (en) 2016-02-03
JP6496296B2 (ja) 2019-04-03
AU2020203245A1 (en) 2020-06-04
CN105797158A (zh) 2016-07-27
US20150141362A1 (en) 2015-05-21
WO2012034132A3 (en) 2012-06-07
JP2019070653A (ja) 2019-05-09
BR112013005806A2 (pt) 2018-01-30
JP6389036B2 (ja) 2018-09-12
CA2810998C (en) 2024-04-09
HUE028977T2 (en) 2017-02-28
KR102511807B1 (ko) 2023-03-20
CA3176977A1 (en) 2012-03-15
US8895245B2 (en) 2014-11-25
US8691507B2 (en) 2014-04-08
JP2023153949A (ja) 2023-10-18
DK2614369T3 (en) 2016-05-02
US20180271892A1 (en) 2018-09-27
US20120071418A1 (en) 2012-03-22
RU2017113351A3 (ru) 2020-08-26
JP2013543114A (ja) 2013-11-28
CA2810998A1 (en) 2012-03-15
EP2614369A4 (en) 2014-04-02
AU2017276284A1 (en) 2018-01-18
KR102373074B1 (ko) 2022-03-11
KR102061353B1 (ko) 2020-01-02
BR112013005806B1 (pt) 2022-05-10
JP2017096944A (ja) 2017-06-01
RU2013115928A (ru) 2014-10-20
AU2011298987B2 (en) 2017-09-28
US20130303555A1 (en) 2013-11-14
CN103261890B (zh) 2016-04-06

Similar Documents

Publication Publication Date Title
RU2017113351A (ru) Ингибиторы ezh2 человека и способы их применения
WO2013132347A3 (en) Improved elisa immunoassay for calprotectin
MX363201B (es) Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico.
WO2008117067A3 (en) Protein signature/markers for the detection of adenocarcinoma
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
PL1776587T3 (pl) Zastosowanie C3A i jego pochodnych jako biomarkera do leczenia gruczolaka i/lub raka jelita grubego; metody diagnostyczne i testy z ich użyciem
RU2010120912A (ru) Устройство датчика для целевых частиц в пробе
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
GB201014837D0 (en) Biomarker signatures and uses thereof
BR112018005812A2 (pt) ?método de imunoensaio para a detecção de um analito, kit de reagentes para detectar um analito por um imunoensaio e uso de um parceiro de ligação marcador-específico?
WO2015031676A3 (en) Integrity testing of hair samples
WO2017194613A3 (en) Method, array and use thereof
RU2011140471A (ru) Способ диагностики эндометриоза и диагностический набор для эндометриоза
BRPI0513596B8 (pt) método e kit para detectar uma infecção micobacteriana em uma amostra de um indivíduo de interesse por meio da detecção de antígeno micobacteriano
MX2019008911A (es) Metodos, matrices y usos de estos.
ZA202002415B (en) Detection of symmetrical dimethylarginine
JP2020514689A5 (ru)
WO2014161910A3 (en) Methods and arrays for use in biomarker detection for prostate cancer
RU2013158667A (ru) Способ диагностики болезни гоше
GB201206323D0 (en) Methods and arrays for use in the same
EP3450979A3 (en) Using phage epitopes to profile the immune response
GB201119585D0 (en) Assay
NO20053276L (no) Fremgangsmate og hjelpemiddel for pavisning av mykoplasma.
MX2018015140A (es) Firmas de biomarcadores de lupus eritematoso sistemico y sus usos.
Yang et al. A biotin–streptavidin signal amplification strategy for a highly sensitive chemiluminescent immunoassay for chicken interferon-γ